-
Bojesen Meyers posted an update a month ago
The reduction of the proliferative rates was attributed to the induction of ROS triggered apoptosis which was associated with activation of Caspase-3, upregulation of Bax and suppression of Bcl-2. Voacangine induced G2/M cell cycle arrest in a dose-dependent manner. Additionally, the anticancer effects of Voacangine on oral cancer cells were exerted through the inhibition of PI3K/AKT signaling cascade.
Taken all together, we conclude that Voacangine is a potent anticancer molecule and may be utilized for the development of systemic therapy for oral cancer.
Taken all together, we conclude that Voacangine is a potent anticancer molecule and may be utilized for the development of systemic therapy for oral cancer.
This study aimed to observe the effect of neo-adjuvant chemotherapy on the improvement of oral cancer patients and investigate the predictive value of miR-182 on its efficacy.
A total of 143 patients with advanced oral cancer admitted to Yidu Central Hospital of Weifang from September 2015 to July 2017 formed the study group. Among them, there were 62 cases in the control group (surgery+postoperative radiotherapy) and 81 cases in the study group (preoperative neo-adjuvant chemotherapy+surgery+postoperative radiotherapy). The treatment effect and adverse reactions of patients were compared between the two groups. RT-PCR was used to detect the expression levels of serum miR-182 of patients before and after treatment. The 1-year survival of patients in the two groups was recorded and compared by follow-up.
The total effective rate of patients in the study group was significantly higher than that of patients in the control group (p<0.05). The incidence of adverse reactions of patients in the study group ioration of oral cancer and is a good indicator for predicting the treatment efficacy of patients with oral cancer.
Oral cancer is one among the devastating types of malignancies and imposes tremendous disease burden on humans. This study was undertaken to investigate the anticancer properties of a plant-derived flavanone, Blumeatin, against human oral cancer cells. Additionally, this study also attempted to unreveal the molecular mechanisms responsible for the anticancer properties of this molecule.
MTT assay was used for the assessment of cell viability. Transwell and wound healing assays were used for the determination of cell invasion and migration, respectively. Comet assay was used for the determination of cell viability. Transmission electron microscopy (TEM) analysis was done to assess the induction of autophagy. The protein expression was determined by western blot analysis.
Blumeatin inhibited the growth of SCC-4 oral cancer cells with minimal cytotoxic effects against the normal hTRET-OME cells. The flow cytometric analysis showed that Blumeatin triggers DNA damage in the SCC-4 cells. Blumeatin also activated autophagy in SCC-4 cells which was accompanied with upregulation of LC3B and Beclin 1. This molecule also increased ROS and decreased the MMP levels in human SCC-4 cells. The effects of Blumeatin were also examined on the migration and invasion of the SCC-4 cells and it was revealed that the molecule suppresses both migration and invasion of the SCC-4 oral cancer cells.
This study indicates that Blumeatin exhibits potent anticancer effects and points towards its use in the development of a new systemic therapy for oral cancer.
This study indicates that Blumeatin exhibits potent anticancer effects and points towards its use in the development of a new systemic therapy for oral cancer.
To investigate the efficacy of second-line regimen in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL), and to analyze relevant prognostic factors.
The clinical data of 105 patients with relapsed or refractory DLBCL admitted and treated from July 2004 to June 2016 were retrospectively reviewed, the response rate after chemotherapy was assessed, and overall survival (OS) was calculated using Kaplan-Meier method. Moreover, Cox regression model was adopted for multivariate analysis, so as to find the independent prognostic factors influencing patient’s OS.
Among the 105 patients, there were 67 males and 38 females, with a median age of 57.54 years. There were 31 cases of CR and 21 cases of PR, and the objective response rate (ORR) was 49.5%. In addition, early progression or recurrence <12 months of relapsed or refractory DLBCL and high-risk international prognostic index (IPI) were the negative factors for response rate to chemotherapy. At the end of follow-up, the median OS of thesk IPI is an independent risk factor influencing the survival of patients with relapsed or refractory DLBCL, and response rate after chemotherapy is an independent prognostic indicator for extending the OS of patients.
To explore the efficacy of different regimens in nasal natural killer (NK)/T-cell lymphoma (NNKTL) and their effects on the serum inflammation and prognosis of patients.
146 NNKTL patients admitted to and treated in the Oncology Department of our hospital from January 2010 to December 2014 were randomly enrolled and divided into chemotherapy group (group A) and concurrent chemoradiotherapy group (group B). The expression levels of interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-α) before and after treatment were detected, the short-term efficacy was followed up and analyzed, and the correlation between the two was statistically analyzed.
In group A and group B, the total short-term effective rate was 71.87% and 84.97%, the 5-year overall survival (OS) rate was 39.9% and 66.2%, and the progression-free survival (PFS) rate was 18.1% and 46.9%, respectively. Decursin Treatment regimens, clinical stage, the presence of B symptoms and lactate dehydrogenase (LDH) level were independent factors related to prognosis, and the remission rate after the first-course chemotherapy was an independent factor unrelated to prognosis. After treatment, there was no significant difference in the IL-2 level between the two groups of patients before and after treatment. The expression level of TNF-α after treatment was reduced compared with that before treatment, and the reduction was more obvious in group B.
The short-term efficacy of concurrent chemoradiotherapy favors NNKTL, and the therapy can reduce the expression level of TNF-α.
The short-term efficacy of concurrent chemoradiotherapy favors NNKTL, and the therapy can reduce the expression level of TNF-α.